Voyager Therapeutics Inc (VYGR) — Capital Reinvestment Ratio
Latest as of March 2024:
0.04x
Voyager Therapeutics Inc (VYGR) has a Capital Reinvestment Ratio of 0.04x as of March 2024, meaning it reinvests 0% of its operating cash flow ($58.77 Million) in capital expenditures ($2.14 Million). See Voyager Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.04x
Capex / Operating Cash Flow
Operating Cash Flow
$58.77 Million
USD
Capital Expenditures
$2.14 Million
USD
Data as of
Mar 2024
Most recent filing
Voyager Therapeutics Inc Capital Reinvestment Ratio (2015–2023)
This chart tracks Voyager Therapeutics Inc's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for Voyager Therapeutics Inc (2015–2023)
Year-by-year Capital Reinvestment Ratio for Voyager Therapeutics Inc from 2015 to 2023. For live market cap and broader valuation context, see VYGR stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.04x | $77.92 Million | $3.26 Million | ▼ -73.7% |
| 2019 | 0.16x | $48.67 Million | $7.72 Million | ▲ +535.9% |
| 2015 | 0.02x | $41.30 Million | $1.03 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow